Artemis Growth Partners Appoints James Hayward as Advisory Director
Artemis Growth Partners, an investment firm specializing in regulated medical cannabis, has appointed James Hayward as an Advisory Director. The move signals the maturing phase of the emergent medicinal therapeutics market.
Artemis Growth Partners, a global investment firm focused on regulated medical cannabis and emergent medicinal therapeutics, has appointed James Hayward as an Advisory Director. Hayward brings over 35 years of experience from JPMorgan, where he was instrumental in building the firm's European credit distribution business.
The appointment comes as the global medical cannabis and emergent medicinal therapeutics markets enter a more mature phase. Regulatory frameworks are evolving, particularly in Europe, and investors are increasingly emphasizing governance, capital discipline, and sustainable business models.
At Artemis, Hayward will advise on capital formation, business development, and strategic financing initiatives. He will work alongside Co-Founder and Chief Investment Officer William Muecke and Managing Partner E. Stanton McLean.
Artemis Growth Partners manages over $300 million in assets and has investments across North America, Europe, and other international markets. The firm highlights Hayward's experience in developing credit markets as valuable for the sector's next stage.